Why carry out this study?
|
Cardiac toxicity of immunotherapy is infrequent but potentially fatal. |
Pericardial disease has been associated with immunotherapy specifically in patients with advanced non-small cell lung cancer (NSCLC) on the basis of retrospective pharmacovigilance analysis. |
The association between pericardial effusion and immunotherapy in advanced NSCLC should be confirmed by real-world data. |
What was learned from the study?
|
We observed a higher incidence of pericardial effusion in a real-world population of patients with advanced NSCLC receiving immunotherapy. |
Pericardial effusion is a relatively frequent toxicity of immunotherapy in NSCLC and these patients should be referred to a cardio-oncology team. |
Introduction
Methods
Results
Age (years) median (range) | 70 (43–81) |
Sex (F/M) | 36/24 |
Cancer stage (n/%) | |
IIIB | 6/60 (10%) |
IV | 54/60 (90%) |
Histology (n/%) | |
Adenocarcinoma | 39/60 (65%) |
Squamous cell carcinoma | 17/60 (28%) |
Large cell carcinoma/NOS | 4/60 (7%) |
Treatment (n/%) | |
Nivolumab | 52/60 (86.7%) |
2nd line | 45/52 (86.5%) |
3rd line | 7/52 (13.5%) |
Pembrolizumab* | 8/60 (13.3%) |
Discussion
ICIs | Chemotherapy | |
---|---|---|
Overall incidence (n/%) | 4/60 (6.7%) | 2/60 (3.3%) |
Adjusted incidencea (n/%) | 2/60 (3.3%) | 1/60 (1.6%) |
Onset time (median [range]) | 40 (44–36) days | 65 (65–65) daysb |